Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials
European Journal of Neurology · 2023
DOI: 10.1111/ene.15820 ↗At a glance
Journal article in European Journal of Neurology, 2023. Written by Iyas Daghlas and 1 co-authors. Institution: Department of Neurology, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Venous Thromboembolism, Thrombosis, Ischemic Stroke. Cited 14 times so far (Crossref); 15 references.
Abstract (original language)
Background
Factor XI (FXI) is a promising therapeutic target for the prevention of thrombotic disease without increasing bleeding risk.
Methods
We performed Mendelian randomization (MR) analyses to investigate the association of genetically predicted reductions in FXI levels with risk of venous thromboembolism, ischemic stroke, bleeding outcomes, and lifespan.
Results
Genetically predicted reductions in FXI levels were associated with lower risk of ischemic stroke (odds ratio per 1 standard deviation (SD) lower serum FXI 0.90, 95% confidence interval 0.87–0.93, p = 1.59 × 10 −11 ), and venous thromboembolism (0.54, 0.49–0.59, p = 2.13 × 10 −39 ) but did not associate with increased bleeding risk ( p > 0.16). Genetically predicted reductions in serum FXI levels associated with longer lifespan (0.37 years per 1 SD lower serum FXI, 0.13–0.61, p = 0.003).
Conclusions
These genetic data support FXI as a potentially efficacious and safe therapeutic target and anticipate positive results from ongoing phase 3 clinical trials.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, University of California San Francisco, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
ORCID profiles: Iyas Daghlas
Cite
APA
Daghlas, I., & Gill, D. (2023). Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. https://doi.org/10.1111/ene.15820
Vancouver
Daghlas I, Gill D. Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. 2023. doi:10.1111/ene.15820
BibTeX
@article{Daghlas2023,
author = {Daghlas, Iyas and Gill, Dipender},
title = {Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15820}
}
EUVIMED